Johnson & Johnson COVID-19 Vaccine
According to a new analysis posted online by the FDA, the Johnson & Johnson (JNJ) vaccine is providing strong protection against severe disease and death related to COVID-19 infection. The vaccine may reduce the spread of the virus from vaccinated people. The vaccine is said to have a 72% efficacy rate in the U.S. and 64% in South Africa.
The vaccine has demonstrated 86% efficacy against severe forms of COVID-19. The FDA could authorize selling the vaccine as early as this Saturday, depending on the voting by the FDA vaccine advisory panel tomorrow, Friday, February 26, 2021.